Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

FDA approval for CORIS……. finally

Nanosonics
3:27pm
March 20, 2025
The long-awaited approval for NAN’s flexible endoscope CORIS has been received, derisking the opportunity to diversify and expand and further embed itself as a disinfection solutions leader within the hospital. The flexible endoscope market presents a significant opportunity, and we view CORIS as having strong potential given its advantages over current standards. However, adoption rates are typically not linear so further updates over the coming 12 months will aid the shaping of market expectations. We raise our valuation and target price to A$5.50 (from A$4.50) following reduced risks post-approval. This remains a strong business with a dominant market position, high-margin recurring revenue, and potential for further market penetration. Remains a key stock to watch.

Share price weakness provides buying opportunity

Judo Capital Holdings
3:27pm
March 20, 2025
Since February JDO’s share price has drifted lower alongside its banking sector peers, and then stepped down today with the overnight block trade exit of two pre-IPO investors. We take this share price weakness as a buying opportunity. Nothing fundamentally has changed in the business as a result of these shareholder exits. Upgrade to ADD with potential TSR at current prices of c.21%. No change to forecasts or DCF-based target price of $2.08.

Investing for growth requires patience

Webjet Group Limited
3:27pm
March 19, 2025
WJL has reiterated its FY25 guidance, however FY26 is now a year of investment and not acceleration. We have made material revisions to our FY26 forecasts. With its Strategy Presentation, WJL has laid out its 5-year growth plan which is targeting to double TTV by FY30 (materially above consensus estimates). Its strategy is all about capturing the full travel wallet through higher margin ancillary product sales and selling more international vs domestic travel. It also includes offering a more tailored business travel offering. The strategy requires a brand refresh and increased investment in technology, capability and marketing. While the size of the opportunity is material if WJL delivers on its target, execution risk is high. Despite its undemanding fundamentals, given earnings growth is not expected until FY27, WJL is now lacking near term catalysts, in the absence of capital management and/or corporate activity. We move to a Hold rating.

Resetting the business for growth

Myer
3:27pm
March 19, 2025
MYR’s 1H25 result was impacted by the challenging consumer environment as well as operational issues at its National Distribution Centre (NDC). These issues were flagged at the five-month trading update in January. Sales were broadly flat yoy at $1.8bn, while gross profit margin was down ~50bps driven by mix shift, DC costs and increased promotional activity. EBIT was negatively impacted by $12m due to operational issues at the NDC. NPAT was down 18% yoy to $42.4m. MYR has completed a strategic review, a new leadership team has been put in place to drive the growth strategy moving forward. The combination with Apparel Brands has been completed with the group to record combined results from 2H25.

Well placed to weather the cycle lows

New Hope Group
3:27pm
March 18, 2025
NHC’s 1H25 result was typically solid with capital management the key surprise. The 1H dividend materially beat expectations, and we like the optionality to accrete EPS/value through current weakness via the new on-market buyback. Maintained FY25 guidance offers comfort amid weaker prices, supporting NHC’s cost and margin advantages versus key peers. NHC remains too cheap here, but the sluggish thermal coal outlook is challenging price floors the into shoulder season and NHC does lack a near-term catalyst.

A good couple of months

Generation Development Group
3:27pm
March 18, 2025
GDG has released its 1H25 result and also announced the acquisition of Evidentia. Overall, we saw the 1H25 result as strong across the board, whilst the Evidentia acquisition solidifies GDG’s leading position in the attractive Managed Account space. We increase our GDG FY25F/FY26F EPS by 3%-7% on incorporation of the Evidentia acquisition into our forecasts, and also earnings changes from the 1H25 result. We lift our GDG target price to A$5.59 (previously A$4.75). GDG has a strong structural growth story, and management continue to execute well. With >10% upside to our target price, we maintain our ADD recommendation.

El Golden Chile

Tesoro Gold
3:27pm
March 17, 2025
Coverage of TSO initiated with a SPECULATIVE BUY rating, target price A$0.11ps. TSO’s 1.5Moz Ternera deposit exhibits strong fundamentals, indicative of producing +90kozpa at an AISC of US$1,068/oz whilst generating +A$130m EBITDA per annum. Ternera is free of fatal flaws with plenty of catalysts (drill results, MRE update and PFS) whilst backed by gold mining major Goldfields (17.5%). Chile is a reputable mining jurisdiction with an established mining code, skilled workforce and royalty free gold production.

The final piece of Queensland’s energy puzzle?

Omega Oil & Gas
3:27pm
March 17, 2025
We initiate research coverage on Omega Oil & Gas (OMA) with a Speculative Buy rating and A$0.64 target price. OMA’s flagship Canyon Gas Project has a ~1.7 TCFe resource located strategically close to the east coast gas market. Early frac results from Canyon-1H are encouraging, with flowback now underway. OMA is trading at a discounted A$0.07/GJe (vs undeveloped peers at A$0.21/GJe). Gas producers trade on A$0.77/GJe showing the ultimate ‘size of the prize’.

Getting on with it

Neurizon Therapeutics
3:27pm
March 17, 2025
NUZ is planning to commence two animal studies in the coming weeks which are expected to take four months from start to finish. The studies aim to address the questions FDA placed on NUZ-001 around systemic exposure. Positive data here is required to remove the roadblock currently in the way on its entry into the HEALEY ALS Platform trial. The delays push timelines to trial commencement by ~6 months, and to the end of the 12-month buffer we originally placed on the program for unforeseen delays. Key here will be positive feedback from the FDA which aligns with the studies NUZ will have already commenced. No changes to forecasts although note the additional timelines to trial commencement due to the additional studies sit at the limit of our model assumptions.

International Spotlight

Adobe Inc.
3:27pm
March 17, 2025
Incorporated in 1983, Adobe operates as a globally diversified software company. It operates through the following business segments: 1) Digital Media, which offers creative cloud services (including software such as Photoshop, Adobe Illustrator, Adobe Premiere Pro and Acrobat); 2) Digital Experience, which provides solutions including analytics, social marketing, media optimisation etc, and 3) Publishing and Advertising, which includes legacy products for eLearning and technical document publishing, web application development.

News & Insights

Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more
Michael Knox outlines the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and his own analysis for Australia.

Today, I’m presenting the first page of my updated presentation, which focuses on GDP growth and inflation expectations for major economies. Before diving into that, I want to clarify a point about U.S. trade negotiations that has confused some media outlets.

In the previous Trump Administration ,there was single trade negotiator, Robert Lighthizer, held a cabinet position with the rank of Ambassador. This time, to expedite negotiations and give them more weight, Trump has appointed two additional cabinet-level officials to handle trade talks with different regions. For Asian economies, Scott Bessent and Ambassador Jamison Greer, who succeeded Lighthizer and previously served on the White House staff, are managing negotiations, including those with China. For Europe, Howard Lutnick, the Commerce Secretary, and Ambassador Greer are negotiating with the European Trade Representative. When the EU representative visits Washington, D.C., they meet with Lutnick and Greer, while Chinese or Japanese representatives engage with Bessent and Greer.

In my presentation today, I’m outlining the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and my own analysis for Australia.

For the U.S., the best-case scenario is a soft landing, with growth slowing but remaining positive at 1.3% this year and rising to 1.7% next year. This slowdown allows the Federal Reserve to continue cutting interest rates, leading to a decline in the U.S. dollar. This in turn ,triggers a recovery in commodity prices. These prices have stabilized and are now trending upward, with an expected acceleration as the dollar weakens.

U.S. headline inflation is projected to be just below 3% next year, with higher figures this year driven by tariff effects.



Global Economic Perspective

In the Euro area, growth is accelerating slightly, from just under 1% this year to 1.2% next year, with inflation expected to hit the 2% target this year and dip to 1.9% next year.

China’s GDP growth is forecast  at 4% for both this year and next, a step down from previous 5% rates, reflecting a significant slump in domestic demand and very low inflation  Chinese Inflation is only  :   0.2% last year, 0.4% this year, and 0.9% next year.  Despite a massive fiscal push, with a budget deficit around 8% of GDP, China’s debt-to-GDP ratio is rising faster than the U.S.. Yet this is  yielding more modest  domestic growth.

India, on the other hand, continues to outperform, with 6.5% GDP growth last year, 6.2% this year, and  6.3%  next year, surpassing earlier projections.

Read more
In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia.

Positive earnings surprise

In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia. For all the volatility in markets caused by US trade policy, the results were positive. For all the 187 high profile and blue-chip companies in our International Watchlist, the median EPS beat vs consensus was 3.2%, nearly twice that recorded in the December quarter (1.8%). 37% of companies exceeded consensus EPS expectations by more than 5% and only 9% missed by more than 5%. Communication Services was the most positive sector, led by Magnificent 7 companies Alphabet and Meta Platforms. The median EPS beat in that sector was 13%. Consumer Discretionary was the biggest disappointment (though only a mild one) with EPS falling 0.6% short of analyst estimates on a median basis.

Alphabet and Meta among the best performers

Across our Watchlist, some of the best performing stocks in terms of EPS beats were Alphabet, Boeing, Uniqlo-owner Fast Retailing, Meta Platforms, Newmont and The Walt Disney Company. Notable misses came from insurance broker Aon, BP, PepsiCo, Starbucks, Tesla and UnitedHealth. The latter saw by far the worst share price performance over reporting season, its earnings weakness compounded by the resignation of its CEO and the launch of a fraud investigation by the Department of Justice. British luxury fashion label Burberry had the best performing share price as it gains traction in its turnaround plan.

Tariffs were the main talking point (of course)

The timing of President Trump’s ‘Liberation Day’ on 2 April, just before the March quarter results started rolling in, guaranteed that US tariffs would be the main talking point throughout reporting season. Most companies took the line that higher tariffs presented a material risk to global growth and inflation. The rapidly shifting sands of US trade policy mean the impact of tariffs is highly uncertain. This didn’t stop many companies from trying to estimate the impact on their profits. This ranged from the very precise ($850m said RTX) to the extremely vague (‘a few hundred million dollars’ hazarded Abbott Laboratories). The rehabilitation of AI as a systemic driver of long-term value was a key theme of reporting season, with many companies reporting what Palantir Technologies described as an ‘unstoppable whirlwind of demand’ and others indicating an increase in planned AI investment. The deterioration in consumer confidence was another key talking point, though most companies could only express concern about a possible future softening in demand rather than any actual evidence of a hit to sales.

Our International Focus List continues to outperform

In this report, we also report on the performance of the Morgans International Focus List, which is now up 25.3% since inception last year, outperforming the benchmark S&P 500 by 20.4%.


Morgans clients receive exclusive insights such as access to our latest International Reporting Season article.

Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more